Diffusion MRI Phenotypes Predict Overall Survival Benefit from Anti-VEGF Monotherapy in Recurrent Glioblastoma: Converging Evidence from Phase II Trials

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Clinical Cancer Research

• Publication date

  2017-06-27

• Fields of study

  Medicine

• Identifiers
  DOI 10.1158/1078-0432.CCR-16-2844PMID 28655794PMCID PMC5626594
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Onartuzumab Plus Bevacizumab Versus Placebo Plus Bevacizumab in Patients With Recurrent Glioblastoma: Efficacy, Safety, and Hepatocyte Growth Factor and O6-Methylguanine-DNA Methyltransferase Biomarker Analyses.

  2017cited by this paper
• Baseline pretreatment contrast enhancing tumor volume including central necrosis is a prognostic factor in recurrent glioblastoma: evidence from single and multicenter trials

  2017cited by this paper
• Pivotal role for decorin in angiogenesis.

  2015cited by this paper
• Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials.

  2015cited by this paper
• Antiangiogenic Therapy for Glioblastoma: Current Status and Future Prospects

  2014cited by this paper
• Report of the Jumpstarting Brain Tumor Drug Development Coalition and FDA clinical trials neuroimaging endpoint workshop (January 30, 2014, Bethesda MD).

  2014cited by this paper
• Pretreatment ADC Histogram Analysis Is a Predictive Imaging Biomarker for Bevacizumab Treatment but Not Chemotherapy in Recurrent Glioblastoma

  2014cited by this paper
• Contrast-enhanced T1-weighted digital subtraction maps combined with diffusion MRI to identify recurrent glioblastoma patients that benefit from bevacizumab therapy.

  2014cited by this paper
• Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial.

  2014cited by this paper
• Use of statins and the risk of death in patients with prostate cancer.

  2014cited by this paper
• Recurrent glioblastoma treated with bevacizumab: contrast-enhanced T1-weighted subtraction maps improve tumor delineation and aid prediction of survival in a multicenter clinical trial.

  2014cited by this paper
• Nonlinear distortion correction of diffusion MR images improves quantitative DTI measurements in glioblastoma

  2014cited by this paper
• Acquired Resistance to Anti-VEGF Therapy in Glioblastoma Is Associated with a Mesenchymal Transition

  2013cited by this paper
• Quantitative analysis of type I collagen fibril regulation by lumican and decorin using AFM.

  2013cited by this paper
• Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma.

  2013cited by this paper
• Differential Gene Expression in Glioblastoma Defined by ADC Histogram Analysis: Relationship to Extracellular Matrix Molecules and Survival

  2012cited by this paper
• VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complex.

  2012cited by this paper
• Apparent diffusion coefficient histogram analysis stratifies progression-free and overall survival in patients with recurrent GBM treated with bevacizumab: a multi-center study

  2012cited by this paper
• Antiangiogenic Therapy for Glioblastoma

  2012cited by this paper
• Abstract 4758: Inhibition of checkpoint kinase 1 (Chk1) as a potential therapeutic for pediatric neuroblastoma

  2011cited by this paper
• Phase II study of aflibercept in recurrent malignant glioma: a North American Brain Tumor Consortium study.

  2011cited by this paper
• VEGF and c-Met blockade amplify angiogenesis inhibition in pancreatic islet cancer.

  2011cited by this paper
• Serial magnetic resonance spectroscopy reveals a direct metabolic effect of cediranib in glioblastoma.

  2011cited by this paper
• ADC histograms predict response to anti-angiogenic therapy in patients with recurrent high-grade glioma

  2011cited by this paper
• Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma.

  2010cited by this paper
• Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice.

  2009cited by this paper
• Recurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatment.

  2009influential reference
• Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma.

  2009cited by this paper
• A "vascular normalization index" as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients.

  2009cited by this paper
• Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma.

  2009cited by this paper
• Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.

  2009cited by this paper
• HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion.

  2008cited by this paper
• AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.

  2007cited by this paper
• Angiogenesis in brain tumours

  2007cited by this paper
• Inhibition of hypoxia inducible factor-1α (HIF-1α) decreases vascular endothelial growth factor (VEGF) secretion and tumor growth in malignant gliomas

  2006cited by this paper
• Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.

  2005cited by this paper
• MRI diffusion coefficients in spinal cord correlate with axon morphometry

  2005cited by this paper
• Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases.

  2004cited by this paper
• Vascular endothelial growth factor: basic science and clinical progress.

  2004cited by this paper
• Nuclear magnetic resonance (NMR) measurement of the apparent diffusion coefficient (ADC) of tissue water and its relationship to cell volume changes in pathological states.

  2004cited by this paper
• Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy.

  2002cited by this paper
• The basis of anisotropic water diffusion in the nervous system – a technical review

  2002cited by this paper
• Pulsed-Gradient Spin−Echo 1H and 19F NMR Ionic Diffusion Coefficient, Viscosity, and Ionic Conductivity of Non-Chloroaluminate Room-Temperature Ionic Liquids

  2001cited by this paper
• Angiogenesis in cancer and other diseases

  2000cited by this paper
• Extracellular space structure revealed by diffusion analysis.

  1998cited by this paper
• Dynamic changes in water ADC, energy metabolism, extracellular space volume, and tortuosity in neonatal rat brain during global ischemia

  1996cited by this paper
• Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo

  1992cited by this paper
• Viscosity and self-diffusion coefficient of linear polyethylene

  1987cited by this paper
• Published online in Wiley InterScience (www.interscience.wiley.com). DOI:10.1002/nbm.782 Review Article

  year unknowncited by this paper

• Rapid early progression of glioblastoma: evaluation of a novel prognostic radiologic biomarker

  2025cites this paper
• Advanced imaging characterization of post-chemoradiation glioblastoma stratified by diffusion MRI phenotypes known to predict favorable anti-VEGF response

  2025cites this paper
• Early Tumor Shrinkage and Depth of Response as Predictive Markers of Treatment Response and Prognosis in Solid Tumors

  2025influential citation
• Predictive potential of MRI in differentiating the predominant component in biphasic pleural mesothelioma.

  2024cites this paper
• The QIBA Profile for Diffusion-Weighted MRI: Apparent Diffusion Coefficient as a Quantitative Imaging Biomarker.

  2024cites this paper
• Radio-pathomic estimates of cellular growth kinetics predict survival in recurrent glioblastoma

  2024cites this paper
• Survival prediction using apparent diffusion coefficient values in recurrent glioblastoma under bevacizumab treatment: an updated systematic review and meta-analysis

  2024cites this paper
• Unlocking Hope: Anti-VEGFR inhibitors and their potential in glioblastoma treatment.

  2024cites this paper
• Revealing the biology behind MRI signatures in high grade glioma

  2023cites this paper
• Characterization of DNA Damage Repair Related Signature and Molecular Feature in Low-Grade Gliomas to Aid Chemotherapy and Drug Discovery.

  2023cites this paper
• Diagnostic Approaches to Adult-Type Diffuse Glial Tumors: Comparative Literature and Clinical Practice Study

  2023cites this paper
• Small pretreatment lesion size and high sphericity as favorable prognostic factors after laser interstitial thermal therapy in brain metastases.

  2023cites this paper
• Depth of radiographic response (DpR) and time to tumor regrowth (TTG) predicts overall survival following anti-VEGF therapy in recurrent glioblastoma.

  2023cites this paper
• Molecular and functional imaging in cancer-targeted therapy: current applications and future directions

  2023cites this paper
• Endocannabinoids are potential inhibitors of glioblastoma multiforme proliferation.

  2023cites this paper
• Prognostic value of preoperative diffusion restriction in glioblastoma

  2023cites this paper
• Early volumetric, perfusion, and diffusion MRI changes after mutant isocitrate dehydrogenase (IDH) inhibitor treatment in IDH1-mutant gliomas

  2022cites this paper
• Congress of Neurological Surgeons Systematic Review and Evidence-Based Guidelines on the Management of Progressive Glioblastoma in Adults: Update of the 2014 Guidelines

  2022cites this paper
• Pretreatment ADC Histogram Analysis as a Prognostic Imaging Biomarker for Patients with Recurrent Glioblastoma Treated with Bevacizumab: A Systematic Review and Meta-analysis

  2022cites this paper
• Imaging Advances for Central Nervous System Tumors.

  2021cites this paper
• Validation of diffusion MRI as a biomarker for efficacy using randomized phase III trial of bevacizumab with or without VB-111 in recurrent glioblastoma

  2021cites this paper
• Imaging Surveillance of Gliomas: Role of Basic and Advanced Imaging Techniques.

  2021cites this paper
• Congress of Neurological Surgeons systematic review and evidence-based guidelines update on the role of imaging in the management of progressive glioblastoma in adults

  2021cites this paper
• Dynamic contrast-enhanced MRI may be helpful to predict response and prognosis after bevacizumab treatment in patients with recurrent high-grade glioma: comparison with diffusion tensor and dynamic susceptibility contrast imaging

  2021cites this paper
• Early Response to Chemotherapy in Malignant Pleural Mesothelioma Evaluated Using Diffusion-Weighted Magnetic Resonance Imaging: Initial Observations

  2021cites this paper
• Diffusion MRI is an early biomarker of overall survival benefit in IDH wild-type recurrent glioblastoma treated with immune checkpoint inhibitors.

  2021cites this paper
• Advanced Imaging Techniques for Radiotherapy Planning of Gliomas

  2021cites this paper
• Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions.

  2021cites this paper
• Imaging Glioblastoma Posttreatment: Progression, Pseudoprogression, Pseudoresponse, Radiation Necrosis.

  2021cites this paper
• Advancing Imaging to Enhance Surgery: From Image to Information Guidance.

  2021cites this paper
• Therapeutic approaches to overcome temozolomide resistance in glioblastoma

  2021cites this paper
• Imatinib-induced pancreatic hypertrophy in patients with gastrointestinal stromal tumor: Association with overall survival.

  2020cites this paper
• Identification of Early Response to Anti-Angiogenic Therapy in Recurrent Glioblastoma: Amide Proton Transfer-weighted and Perfusion-weighted MRI compared with Diffusion-weighted MRI.

  2020cites this paper
• Glioblastoma in Adults: A Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) Consensus Review on Current Management and Future Directions.

  2020cites this paper
• Diffusion Magnetic Resonance Imaging Phenotypes Predict Overall Survival Benefit From Bevacizumab or Surgery in Recurrent Glioblastoma With Large Tumor Burden.

  2020cites this paper
• Validation of diffusion MRI phenotypes for predicting response to bevacizumab in recurrent glioblastoma: post-hoc analysis of the EORTC-26101 trial.

  2020cites this paper
• Diffusion kurtosis imaging for characterizing tumor heterogeneity in an intracranial rat glioblastoma model

  2020cites this paper
• Decorin expression is associated with predictive diffusion MR phenotypes of anti-VEGF efficacy in glioblastoma

  2020cites this paper
• MRI and 18FET-PET Predict Survival Benefit from Bevacizumab Plus Radiotherapy in Patients with Isocitrate Dehydrogenase Wild-type Glioblastoma: Results from the Randomized ARTE Trial

  2020cites this paper
• Predicting Survival in Glioblastoma Patients Using Diffusion MR Imaging Metrics—A Systematic Review

  2020cites this paper
• Multiparameter quantitative histological MRI values in high-grade gliomas: a potential biomarker of tumor progression

  2020cites this paper
• Advanced magnetic resonance imaging to support clinical drug development for malignant glioma.

  2020cites this paper
• 뇌종양 영상의 현재와 미래

  2020cites this paper
• NEC 32.2 (Vogelbaum) Glioblastoma, Part I: Surgical Management and Adjuncts Advancing Imaging to enhance Surgery: from image to information guidance

  2020cites this paper
• ADC quantification to classify patients candidate to receive bevacizumab treatment for recurrent glioblastoma

  2019cites this paper
• Advanced Physiologic Imaging: Diffusion – Theory and Applications

  2019cites this paper
• Whole genome and biomarker analysis of patients with recurrent glioblastoma on bevacizumab: A subset analysis of the CABARET trial.

  2019cites this paper
• Association Between VEGF Expression and Diffusion Weighted Imaging in Several Tumors—A Systematic Review and Meta-Analysis

  2019cites this paper
• Imaging Glioblastoma Posttreatment: Progression, Pseudoprogression, Pseudoresponse, Radiation Necrosis.

  2019cites this paper
• Effect of bevacizumab against cystic components of brain tumors

  2019cites this paper
• Imaging-guided precision medicine in glioblastoma patients treated with immune checkpoint modulators: research trend and future directions in the field of imaging biomarkers and artificial intelligence

  2019cites this paper
• Magnetic resonance imaging texture analyses in lower-grade gliomas with a commercially available software: correlation of apparent diffusion coefficient and T2 skewness with 1p/19q codeletion

  2019cites this paper
• Baseline T1 hyperintense and diffusion-restricted lesions are not linked to prolonged survival in bevacizumab-treated glioblastoma patients of the GLARIUS trial

  2019cites this paper
• Bevacizumab for recurrent anaplastic oligodendroglial tumors

  2019cites this paper
• Pre-operative apparent diffusion coefficient values and tumour region volumes as prognostic biomarkers in glioblastoma: correlation and progression-free survival analyses

  2019cites this paper
• Radiogenomics for Precision Medicine With a Big Data Analytics Perspective

  2019cites this paper
• Imaging in neuro-oncology

  2018cites this paper
• Bevacizumab and Glioblastoma: Past, Present, and Future Directions

  2018cites this paper
• Epidermal Growth Factor Receptor Extracellular Domain Mutations in Glioblastoma Present Opportunities for Clinical Imaging and Therapeutic Development.

  2018cites this paper
• Validation of postoperative residual contrast-enhancing tumor volume as an independent prognostic factor for overall survival in newly diagnosed glioblastoma

  2018cites this paper
• Mono-exponential, diffusion kurtosis and stretched exponential diffusion MR imaging response to chemoradiation in newly diagnosed glioblastoma

  2018cites this paper
• The siren song of bevacizumab: swan song or clarion call?

  2018cites this paper
• Inhibition of autophagy potentiated the anti-tumor effects of VEGF and CD47 bispecific therapy in glioblastoma

  2018cites this paper
• Conventional and advanced magnetic resonance imaging in patients with high-grade glioma.

  2018cites this paper